博瑞医药涨2.02%，成交额3.19亿元，主力资金净流入1714.71万元

Group 1 - The core viewpoint of the news is that 博瑞医药 (Borui Pharmaceutical) has experienced significant stock price fluctuations and changes in shareholder structure, indicating potential investment opportunities and challenges [1][2][3] Group 2 - As of November 14, 博瑞医药's stock price increased by 2.02% to 55.49 CNY per share, with a total market capitalization of 23.478 billion CNY [1] - The company has seen a year-to-date stock price increase of 84.33%, with a recent 5-day increase of 4.27% and a 20-day increase of 8.17%, but a significant 60-day decline of 51.15% [1] - The company reported a revenue of 874 million CNY for the first nine months of 2025, a year-on-year decrease of 10.50%, and a net profit of 50.32 million CNY, down 71.64% year-on-year [2] - 博瑞医药's main business revenue composition includes 89.90% from product sales, 6.77% from technical rights and services, and 3.33% from other sources [1] - The number of shareholders increased by 104.44% to 19,600 as of September 30, 2025, while the average circulating shares per person decreased by 51.05% to 21,629 shares [2] - The company has distributed a total of 246 million CNY in dividends since its A-share listing, with 129 million CNY distributed in the last three years [3] - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 547.10 thousand shares to 8.7219 million shares [3]